EC approves Basilea's Cresemba

Basilea Pharmaceutica AG (SIX:BSLN) said the European Commission approved an MAA for Cresemba isavuconazonium to treat adults with invasive aspergillosis and adults with mucormycosis for whom amphotericin B is not appropriate. Basilea said it expects to launch the broad-spectrum water-soluble azole antifungal early next year.

In July, CHMP recommended approval of Cresemba for the same indications. ...